<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140112</url>
  </required_header>
  <id_info>
    <org_study_id>CNDO 201-101</org_study_id>
    <nct_id>NCT02140112</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder</brief_title>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coronado Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coronado Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, 2-arm, placebo-controlled crossover study in pediatric
      patients with autism spectrum disorder with all patients receiving 16-weeks of TSO treatment
      and 16 weeks of placebo.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A preliminary analysis of data from this trial failed to demonstrate any signal of activity.
  </why_stopped>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Aberrant Behavior Checklist - Irritability (ABC-I) at 16 weeks</measure>
    <time_frame>36 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Trichuris suis ova</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TSO 2500 x 2 doses every 2 weeks followed by TSO 7500 x 6 doses every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 8 doses every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trichuris suis ova</intervention_name>
    <arm_group_label>Trichuris suis ova</arm_group_label>
    <other_name>TSO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, 5 to 17 years of age

          -  Patients must fulfill DSM-V diagnostic criteria for autism spectrum disorder
             ascertained at screening, using a clinical review confirmed by the Autism Diagnosis
             Observation Schedule - Second edition (ADOS-2)

          -  Written informed consent from parent(s) or legal guardian(s) with sufficient
             intellectual capacity to understand the study and support patients' adherence to the
             study procedures must be obtained for patients who are not emancipated. In accordance
             with Institutional Review Board (IRB) requirements, the patient will complete an
             informed assent when developmentally appropriate, to participate in the study before
             conduct of any study-specific procedures.

          -  Patients are able and willing to swallow study medication suspension.

        Exclusion Criteria:

          -  Known diagnosis of syndromal form of Autism (e.g. Rett Syndrome, Childhood
             Disintegrative Disorder, Fragile X Syndrome, etc.)

          -  Patients who cannot discontinue anti-psychotic medication

          -  Patients with current active seizure disorder or who have had a seizure within the
             last 6 months prior to screening

          -  Female patient who is pregnant or breastfeeding or wishing to become pregnant during
             study participation or unwilling to use birth control.

          -  Patients who have received helminthic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southwest Autism Research &amp; Resource Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkansas Children's Hospital Research Institute</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baber Research Group</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center Dept. of Psychiatry, Child Annex</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Red Oak Psychiatry</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>November 3, 2015</last_update_submitted>
  <last_update_submitted_qc>November 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T. suis ova</keyword>
  <keyword>Trichuris suis ova</keyword>
  <keyword>Autism Spectrum Disorder</keyword>
  <keyword>ASD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Autism Spectrum Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>April 18, 2017</submitted>
    <returned>May 22, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

